

ModernGraham Valuation

IDEXX Laboratories,
Inc.



Company Name:

Company Ticker IDXX

Date of Analysis

3/21/2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$19,330,932,847	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	0.85	Fail
3. Earnings Stability	Positive EPS for 10 years prior		Pass
4. Dividend Record	Dividend Payments for 10 years prior		Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	185.34%	Pass
5. Earnings Growth			
6. Moderate PEmg Ratio	PEmg < 20	60.08	Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	-2,138.74	Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.85	Fail
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-5.17	Fail
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Fail
5. Earnings Growth	EPSmg greater than 5 years ago Score		Pass

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

EPSmg	\$3.74
MG Growth Estimate	15.00%
MG Value	\$144.09
MG Value based on 3% Growth	\$54.27
MG Value based on 0% Growth	\$31.81
Market Implied Growth Rate	25.79%

MG Opinion

Current Price	\$224.86
% of Intrinsic Value	156.05%
Opinion	Overvalued
MG Grade	F

Stage 3: Information for Further Research





Net Current Asset Value (NCAV)	-\$10.16
Graham Number	\$0.00
PEmg	60.08
Current Ratio	0.85
PB Ratio	-2,138.74
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links:

ModernGraham tagged articles	Morningstar
Google Finance	MSN Money
Yahoo Finance	Seeking Alpha
GuruFocus	SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$4.67	Next Fiscal Year Estimate	\$3.74
Dec2018	\$4.26	Dec2018	\$3.08
Dec2017	\$2.94	Dec2017	\$2.40
Dec2016	\$2.44	Dec2016	\$2.06
Dec2015	\$2.05	Dec2015	\$1.81
Dec2014	\$1.79	Dec2014	\$1.64
Dec2013	\$1.74	Dec2013	\$1.51
Dec2012	\$1.59	Dec2012	\$1.33
Dec2011	\$1.39	Dec2011	\$1.15
Dec2010	\$1.19	Dec2010	\$0.99
Dec2009	\$1.01	Dec2009	\$0.86
Dec2008	\$0.94	Dec2008	\$0.76
Dec2007	\$0.73	Dec2007	\$0.65
Dec2006	\$0.71	Dec2006	\$0.57
Dec2005	\$0.58	Dec2005	\$0.48
Dec2004	\$0.55	Dec2004	\$0.41
Dec2003	\$0.40	Dec2003	\$0.32
Dec2002	\$0.33	Balance Sheet Information 12/1/2018	
Dec2001	\$0.27	Total Current Assets	\$654,172,000
Dec2000	\$0.26	Total Current Liabilities	\$770,444,000
Dec1999	\$0.21	Long-Term Debt	\$601,348,000
		Total Assets	\$1,537,349,000
		Intangible Assets	\$256,314,000
		Total Liabilities	\$1,546,582,000
		Shares Outstanding (Diluted Average)	87,819,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company [IDEXX Laboratories Inc Valuation – June 2018 \\$IDXX](#)
[IDEXX Laboratories Inc Valuation – Initial Coverage \\$IDXX](#)

Other ModernGraham posts about related companies [Hologic Inc Valuation – March 2019 #HOLX](#)
[Mettler-Toledo International Inc Valuation – March 2019 #MTD](#)
[DaVita Inc Valuation – March 2019 #DVA](#)
[Danaher Corp Valuation – March 2019 #DHR](#)
[Agilent Technologies Inc Valuation – March 2019 #A](#)
[ResMed Inc Valuation – March 2019 #RMD](#)
[Cooper Companies Inc Valuation – March 2019 #COO](#)
[Edwards Lifesciences Corp Valuation – March 2019 \\$EW](#)
[Boston Scientific Corporation Valuation – March 2019 \\$BSX](#)
[Baxter International Inc Valuation – March 2019 \\$BAX](#)